5414002025-04-012025-06-305414002025-04-012025-06-30in-capmkt:OtherExpenses1Member5414002025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15414002025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares541400ZIMLABNOTLISTEDINE518E01015ZIM Laboratories LimitedMain BoardEquity2025-04-012026-03-312025-08-072025-07-31INRLakhsQuarterlyFirst quarterSingle segmentPharmaceutical2025-08-0712:30:002025-08-0719:00:00Not applicable2025-04-012025-06-30UnauditedConsolidated717561000147630007323240002761730001593000079860001461270003303500048635000228758000756644000-243200000-24320000872000-6443000-55710000-187490000000-187490004189000-14560000-187490000-14560000048725800010-0.38-0.3800-0.38-0.380.00470.00780.0026Notes The above unaudited consolidated financial of ZIM Laboratories Limited the Parent or the Company and its subsidiaries together referred to as Group were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 07 August 2025 The above results have been subjected to limited review by Statutory Auditor of the Parent 2 These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard Ind AS notified under the Companies Indian Accounting Standards Rules 2015 as amended as prescribed under Section 133 of the Companies Act 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India SEBI The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures for the year ended 31 March 2025 and the unaudited year to date figures upto 31 December 2024 4 The consolidated financial results of the Group for the quarter and year ended 31 March 2025 and quarter ended 30 June 2024 were reviewed audited by another auditor who expressed an unmodified conclusion/opinion on those results on 20 May 2025 and 03 August 2024 respectively 5 The Board of Directors of the Parent on 04 August 2025 have approved the closure of ZIM Laboratories Middle East DMCC Step Down Subsidiary subject to the approval of relevant regulatory authorities 6 The Group is principally engaged in a sigle business segment which is pharmaceuticals There is no seperate reportable segment as per Ind AS 108 Operating Segments <BR> Place Nagpur Anwar S. Daud <BR> Date 07 August 2025 Managing DirectorOther Expenses228758000Measurements of defined employee benefit plans-1899000-1899000-553000Gain and losses arising from translating the financial statements of foreign expenses5535000553500004189000